Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

famitinib (SHR 1020)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jiangsu Hengrui Pharma

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

‹

›

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	dalpiciclib + SHR 1020 Sensitive: C2 – Inclusion Criteria dalpiciclib + SHR 1020 Sensitive : C2	dalpiciclib + SHR 1020 Sensitive: C2 – Inclusion Criteria dalpiciclib + SHR 1020 Sensitive : C2
CD8 positive	Triple Negative Breast Cancer	CD8 positive	Triple Negative Breast Cancer	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3
PKD1 mutation	Triple Negative Breast Cancer	PKD1 mutation	Triple Negative Breast Cancer	camrelizumab + SHR 1020 Resistant: C3 – Early Trials camrelizumab + SHR 1020 Resistant : C3	camrelizumab + SHR 1020 Resistant: C3 – Early Trials camrelizumab + SHR 1020 Resistant : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3